Insurance Exec: ‘We Are All To Blame’ For Failure Of US Health System

Why It Matters

If successful, Worthy could reshape insurance regulation, driving cost reductions and broader access across the fragmented U.S. health market.

Key Takeaways

• Ascendiun launches Worthy, a lobbying push for health reform.
• Markovich blames insurers for system inefficiencies and high costs.
• Calls for breaking up vertically integrated insurance giants.
• Targets prior‑authorization, admin waste, and drug price transparency.
• Pushes value‑based payments and real‑time digital health records.

Pulse Analysis

The U.S. health‑care system faces mounting pressure from rising premiums, uneven access, and a complex web of insurers, providers, and pharmacy‑benefits managers (PBMs). Recent congressional action on PBM reforms has highlighted the political appetite for change, yet entrenched interests keep the status quo intact. Ascendiun, the parent of Blue Shield of California, leverages its market position to champion a new narrative: insurers are not neutral facilitators but rule‑makers whose structures inflate costs. By spotlighting administrative waste and the notorious prior‑authorization bottleneck, the company frames reform as both a moral and economic imperative.

Worthy, the newly unveiled lobbying platform, builds on Markovich’s prior moves—dropping CVS for Amazon Pharmacy and Cost Plus Drugs, and backing recent PBM legislation. Partnering with entrepreneur Mark Cuban adds a high‑profile voice that amplifies the call for breaking up vertically integrated insurers. The effort seeks concrete policy levers: stricter oversight of insurer‑set rules, incentives for value‑based payment models, and mandates for transparent drug pricing. By positioning insurers as accountable stakeholders, Worthy aims to shift legislative focus from profit preservation to patient‑first outcomes.

If Worthy gains traction, the ripple effects could be profound. Insurers may be forced to modernize provider directories, streamline prior‑authorization through digital tools, and adopt real‑time health records, accelerating the shift toward value‑based care. Such reforms could lower administrative overhead, potentially stabilizing premiums and reducing the financial burden on employers and consumers. However, industry pushback is likely, as breaking up large insurers threatens established revenue streams. The initiative’s success will hinge on coalition‑building with providers, policymakers, and consumer advocates, making it a pivotal test of whether market leaders can drive systemic health‑care transformation.